Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE.

Front Immunol. 2019 Apr 11;10:766. doi: 10.3389/fimmu.2019.00766. eCollection 2019. Review.

2.

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.

Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, Neyns B, Sancho D, Melero I, de Vries IJM.

J Immunother Cancer. 2019 Apr 18;7(1):109. doi: 10.1186/s40425-019-0580-6. Review.

4.

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine.

Mookerjee A, Graciotti M, Kandalaft LE.

Cancers (Basel). 2019 Jan 4;11(1). pii: E40. doi: 10.3390/cancers11010040.

5.

Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?

Martin Lluesma S, Graciotti M, Chiang CL, Kandalaft LE.

Vaccines (Basel). 2018 Nov 23;6(4). pii: E79. doi: 10.3390/vaccines6040079. Review.

6.

In vivo cancer vaccination: Which dendritic cells to target and how?

Chiang CL, Kandalaft LE.

Cancer Treat Rev. 2018 Dec;71:88-101. doi: 10.1016/j.ctrv.2018.10.012. Epub 2018 Oct 25. Review.

PMID:
30390423
7.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
8.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

9.

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.

Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G, Gfeller D.

PLoS Comput Biol. 2017 Aug 23;13(8):e1005725. doi: 10.1371/journal.pcbi.1005725. eCollection 2017 Aug.

10.

Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE.

Biomedicines. 2016 May 3;4(2). pii: E10. doi: 10.3390/biomedicines4020010. Review.

11.

Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

Zsiros E, Dangaj D, June CH, Kandalaft LE, Coukos G.

Oncoimmunology. 2015 Oct 19;5(5):e1062210. doi: 10.1080/2162402X.2015.1062210. eCollection 2016 May.

12.

Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.

Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L.

Cancer Cell. 2015 Oct 12;28(4):529-540. doi: 10.1016/j.ccell.2015.09.006.

13.

Whole Tumor Antigen Vaccines: Where Are We?

Chiang CL, Coukos G, Kandalaft LE.

Vaccines (Basel). 2015 Apr 23;3(2):344-72. doi: 10.3390/vaccines3020344. Review.

14.

Personalized approaches to active immunotherapy in cancer.

Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE.

Biochim Biophys Acta. 2016 Jan;1865(1):72-82. doi: 10.1016/j.bbcan.2015.07.004. Epub 2015 Aug 1. Review.

PMID:
26241169
15.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

Clin Cancer Res. 2015 Jun 15;21(12):2840-50. doi: 10.1158/1078-0432.CCR-14-2777. Epub 2015 Feb 23.

16.

Potential approaches for more successful dendritic cell-based immunotherapy.

Chiang CL, Balint K, Coukos G, Kandalaft LE.

Expert Opin Biol Ther. 2015 Apr;15(4):569-82. doi: 10.1517/14712598.2015.1000298. Epub 2015 Jan 2. Review.

PMID:
25553913
17.

Immunotherapy for ovarian cancer: recent advances and perspectives.

Zsiros E, Tanyi J, Balint K, Kandalaft LE.

Curr Opin Oncol. 2014 Sep;26(5):492-500. doi: 10.1097/CCO.0000000000000111. Review.

PMID:
25036883
18.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.

19.

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, Coukos G.

J Transl Med. 2013 Jun 18;11:149. doi: 10.1186/1479-5876-11-149.

20.

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G.

Oncoimmunology. 2013 Jan 1;2(1):e22664.

Supplemental Content

Loading ...
Support Center